BCR/ABL1 Tyrosine kinase inhibitor mutation screen
BCR/ABL1 Tyrosine kinase inhibitor mutation screen-994
BCR-ABL1 Tyrosine Kinase Inhibitor Resistance
t315i
- Evaluating patients with chronic myelogenous leukemia and Philadelphia chromosome positive B-cell acute lymphoblastic leukemia receiving tyrosine kinase inhibitor (TKI) therapy, who are apparently failing treatment
- Preferred initial test to identify the presence of acquired BCR-ABL1 mutations associated with TKI-resistance
Immediately following collection, mix sample thoroughly by gentle inverting 8 - 10 times, to prevent clotting
- Do not spin
- Submit original tube
Lavender (EDTA), 10mL
Lavender (EDTA), 4mL
- Patient's fusion type (p210, p190, p205 or p230)
- Pertinent clinical history
- Clinical or morphologic suspicion
- Date of collection
- Specimen source (blood or bone marrow)
Molecular Medicare billing request
Hospital clients submitting a request for this assay on an outpatient with Medicare should complete and submit a Molecular Medicare billing request form to notify us of the need for Allina Health Laboratory to bill insurance.
Refrigerated (preferred) - 5 days
Ambient - 3 days
- Gross hemolysis
- Moderately to severely clotted
Reverse Transcription-Polymerase Chain Reaction (RT-PCR) with Sanger Sequencing
An interpretive report will be provided
Hospital clients submitting a request for this assay on an outpatient with Medicare should complete and submit a Molecular Medicare billing request form to notify us of the need for Allina Health Laboratory to bill insurance.